For personal use only

ASX Release

EASTLAND UPDATE

Eastland Medical Systems Ltd (**ASX:EMS**) is pleased to announce the appointment of Mr Michael Stewart as a consultant to assist **Eastland** in strategic planning for the commercialisation of the ArTiMist™ anti-malarial treatment, and to review the Board and management composition to ensure the Company has in place the necessary management and financial resources.

Mr Stewart has a broad corporate and management background and has been extensively involved in bilateral donor funded and World Bank co-financed aid projects in under developed countries.

Mr Stewart has recently completed an extensive review of the Company's activities including meetings in the UK and Germany with parties directly involved in the upcoming Clinical Trials, product manufacture and distribution.

Based on a recommendation to downsize its Board, **Eastland** announces the retirement of Mr David Whitelaw (Non-Executive) and Mr Peter Tiede (Executive) as Directors of **Eastland**. Mr Tiede will continue his key executive role as Chief Financial Officer. This change provides separation between the function of Board and Management and is consistent with best practice Corporate Governance guidelines.

Moving forward, the Company proposes to restructure around a four person Board with a Chief Executive Officer (CEO) reporting to it.

Mr Douglas Sims, who has played a pivotal executive role in securing the rights to ArTiMist™ and NiCoSorb™ and has worked tirelessly to fast track commercialisation of ArTiMist™, wishes to assume a non -executive Board role at the successful conclusion of the Clinical Trials which are scheduled to commence in the near term.

The Company will in due course seek to appoint to an additional Board member with the appropriate pharmaceutical industry experience.

Further information:
Dermot Patterson
Chief Executive Officer
Eastland Medical Systems Ltd
t: +61 (0) 8 9436 9500
f: +61 (0) 8 9436 9505
m: +61 (0) 417 915 511
www.eastlandmedical.com.au

Highlights

- **Phase I Single dose clinical trials for ArTiMist™ were completed in Malaysia in November 2007 with positive results indicating it is safe to use.**
- **Phase I multi-dose clinical trials for ArTiMist™ were undertaken in South Africa in February 2008 with compelling positive results indicating the formulation was well tolerated and showed no adverse effects in any of the trial subjects.**
- **Eastland® is now moving to Clinical Field Trials and Regulatory Approval.**

54 Lindsay St Perth, Western Australia, 6000
PO Box 8027, Perth Business Centre, WA, 6849
T: +61 8 9436 9500 F: +61 8 9436 9505
E: d.patterson@eastlandmedical.com.au